Royalty Pharma plc (NASDAQ:RPRX) Receives Average Rating of “Buy” from Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX) have received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $41.60.

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th.

Royalty Pharma Stock Down 0.8 %

Shares of NASDAQ:RPRX opened at $33.01 on Monday. The company has a 50 day moving average price of $30.87 and a two-hundred day moving average price of $28.41. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The company has a market capitalization of $19.03 billion, a PE ratio of 22.77, a PEG ratio of 2.31 and a beta of 0.47. Royalty Pharma has a 52 week low of $24.05 and a 52 week high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Analysts forecast that Royalty Pharma will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.22 per share. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.67%. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RPRX. Brooklyn Investment Group lifted its position in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 876 shares in the last quarter. Allworth Financial LP raised its holdings in Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 877 shares in the last quarter. Blue Trust Inc. raised its holdings in Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 943 shares in the last quarter. Riverview Trust Co boosted its position in Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,186 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 997 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.